Sign in
WithdrawnPhase 2

Gentian Violet Treatment for Hidradenitis Suppurativa

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Aug 2025
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • Gentian Violet
Record updated
4 September 2025
Why it stopped
Drug company did not approve use of the drug, IRB never approved

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month

Who cannot take part

  • Exclusion criteria include children, absent HS lesions at the time of clinic, and cognitive/physical impairments that would make them unable to assess quality of life factors of the survey

Where in United States

  • Wake Forest School of MedicineWinston-Salem, United States

About the trial

What the trial wants to find out

This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.

The group in the trial

  • Gentian Violet TreatmentTreatment being tested

    A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.

    Treatment: Gentian Violet

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Gentian Violet Treatment on Patients With Hidradenitis Suppurativa
Record updated
4 September 2025